Pharma News

Government to introduce Third Line Treatment of HIV/AIDS in 10 ART Centres across the country

Presently, the first line and second line antiretroviral therapy (ART) is given to HIV/AIDS patients free of cost in all ART Centres across the country. The Technical Resource Group on ART on 27th December, 2013 recommended providing third line antiretroviral therapy for HIV/AIDS patients through 10 centres of excellence across the country. The process for the same has been initiated at Department of AIDS Control.

IMBRUVICA™ gets nod from USFDA for treatment of Chronic Lymphocytic Leukemia - rare blood and bone marrow disease

The U.S. Food and Drug Administration expanded the approved use of Imbruvica™ which contains ibrutinib, for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy on Wednesday, 12 Feb, 2014. Imbruvica™ is manufactured by Pharmacyclics based at Sunnyvale, California.

Mast Therapeutics acquire Aires Pharmaceuticals, Inc.

Mast Therapeutics, Inc., publicly traded biopharmaceutical company headquartered in San Diego, California, announced on 10th feb, 2014 that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure.

41st Annual Conference Of Research Society for study of Diabetes in India RSSDI 2013

RSSDI Annual Scientific Meetings provide a wonderful opportunity to all of us, to meet and interact with each other and share our research, knowledge and clinical experience in all facets of diabetes care. RSSDI-2013 will be yet another enriching scientific experience, where we shall strive hard to meet the expectations of clinicians and researchers alike.

Indian company just did it ! - Zydus pioneers a breakthrough with LIPAGLYN - first molecule from the Indian company

The Zydus Group announced a breakthrough in its research efforts with Lipaglyn TM (Saroglitazar), a novel drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in Type II diabetes, not controlled by statins alone. The drug has been approved for launch in India by the Drug Controller General of India (DCGI). With a novel action that offers lipid and glucose lowering effects in one molecule, Lipaglyn TM is the first Glitazar to be approved anywhere in the world.

Pages